Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)
Public ClinicalTrials.gov record NCT05194540. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Single-arm, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Subjects With Moderate-to-severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this trial is to evaluate the efficacy and safety of tralokinumab administered as subcutaneous (SC) injection by an autoinjector in adults and adolescents (age 12 to 17 years) with moderate-to-severe atopic dermatitis (AD).
Study identification
- NCT ID
- NCT05194540
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 136 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 12, 2022
- Primary completion
- Jun 5, 2023
- Completion
- Jun 20, 2023
- Last update posted
- Mar 10, 2025
2022 – 2023
United States locations
- U.S. sites
- 29
- U.S. states
- 16
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| LEO Pharma Investigator | Birmingham | Alabama | 35205 | — |
| LEO Pharma Investigator | Birmingham | Alabama | 35209 | — |
| LEO Pharma Investigator | Fort Smith | Arkansas | 72916 | — |
| LEO Pharma Investigator | Fountain Valley | California | 92708 | — |
| LEO Pharma Investigator | Fremont | California | 94538 | — |
| LEO Pharma Investigational Site | Inglewood | California | 90301 | — |
| LEO Pharma Investigator | Los Angeles | California | 90025 | — |
| LEO Pharma Investigator | San Diego | California | 92103 | — |
| LEO Pharma Investigator | San Diego | California | 92130 | — |
| LEO Pharma Investigator | Santa Ana | California | 92701 | — |
| LEO Pharma Investigator | Centennial | Colorado | 80111 | — |
| LEO Pharma Investigator | Farmington | Connecticut | 06032 | — |
| LEO Pharma Investigational Site | Hialeah | Florida | 33012 | — |
| LEO Pharma Investigator | Sanford | Florida | 32771 | — |
| LEO Pharma Investigator | Libertyville | Illinois | 60048 | — |
| LEO Pharma Investigator | Overland Park | Kansas | 66210 | — |
| LEO Pharma Investigator | Bangor | Maine | 04401 | — |
| LEO Pharma Investigator | Detroit | Michigan | 48202 | — |
| LEO Pharma Investigator | Portsmouth | New Hampshire | 03801 | — |
| LEO Pharma Investigator | Cortland | New York | 13045 | — |
| LEO Pharma Investigator | Horseheads | New York | 14845 | — |
| LEO Pharma Investigator | Bexley | Ohio | 43209 | — |
| LEO Pharma Investigator | Toledo | Ohio | 43617 | — |
| LEO Pharma Investigator | Tulsa | Oklahoma | 74136 | — |
| LEO Pharma Investigator | Portland | Oregon | 97210 | — |
| LEO Pharma Investigator | Dallas | Texas | 75225 | — |
| LEO Pharma Investigator | Frisco | Texas | 75034 | — |
| LEO Pharma Investigator | San Antonio | Texas | 78218 | — |
| LEO Pharma Investigator | Webster | Texas | 77598 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Atopic Dermatitis trials
Other public records listing Atopic Dermatitis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07765888: A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to-Severe Eczema Recruiting
- NCT04504955: CorEvitas Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness Recruiting
- NCT07783425: A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema Not yet recruiting
- NCT06718101: A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis Active, not recruiting
- NCT07643766: A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis Recruiting
- NCT07748169: An Observational Study of Patients With Dermatologic Disease Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05194540, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 10, 2025 · Synced Sep 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05194540 live on ClinicalTrials.gov.